Anima Biotech

Anima Biotech develops the BioGPU biology resolution platform, where large language models interact with cells through massive parallel visual biology experiments to resolve causal biology across the drug discovery lifecycle. The platform enables AI models to design experiments, observe real cellular responses, and reason causally within living systems through Visual Biology Tokens, a language connecting AI and biology. BioGPU's foundation model is trained on over 2 billion pathway visualizations across 140 cell types and 25 diseases, converting visual biology into textual biological statements that AI can reason about. The platform resolves biology across three dimensions: pathway biology resolution to identify active or inactive pathways driving disease, target biology resolution to understand target function and regulation, and therapeutics biology resolution to evaluate efficacy, resistance, mechanisms, and safety across modalities. The BioGPU Agent designs, executes, and analyzes visual biology experiments at massive parallel scale, running over 1,000 experiments at each iteration across millions of cells. Founded in 2006 and headquartered in the United States, the company has raised approximately $11.5M in Series A funding from investors including NIH, Qbic Fund, National Oceanic and Atmospheric Administration, and HHS. Anima Biotech differentiates itself through its BioGPU platform that enables AI agents to perform experimental reasoning inside cells, converting visual biology experiments into language through a foundation model trained on billions of pathway visualizations for AI-based drug discovery.

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based